華潤醫療控股有限公司
China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The board of directors (the "**Board**") of China Resources Medical Holdings Company Limited (the "**Company**") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the "**Group**") for the six months ended June 30, 2025 (the "**Reporting Period**") as follows:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2025 – unaudited

		For the six months ended 30 June	
		2025	2024
	Note	***RMB'000***	*RMB'000*
REVENUE	*4*	**4,524,803**	4,976,334
Cost of sales		**(3,812,276)**	(3,939,986)
Gross profit		**712,527**	1,036,348
Other income	*5*	**258,181**	69,007
Other gains and losses, net	*6*	**(1,062)**	(9,964)
Selling and distribution expenses		**–**	(2,438)
Administrative and other operating expenses		**(470,261)**	(471,578)
Impairment losses on financial assets, net		**(11,388)**	1,465
Finance costs		**(27,324)**	(39,841)
Share of profits of associates		**47,450**	44,329

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONT'D)
For the six months ended 30 June 2025 – unaudited

		For the six months ended 30 June	
		2025	2024
	Note	***RMB'000***	*RMB'000*
PROFIT BEFORE TAX	*7*	**508,123**	627,328
Income tax	*8*	**(133,875)**	(115,673)
PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		**374,248**	511,655
Attributable to:			
Owners of the Company		**339,521**	433,949
Non-controlling interests		**34,727**	77,706
		374,248	511,655
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*10*		
Basic *(RMB yuan)*		**0.27**	0.34
Diluted *(RMB yuan)*		**0.27**	0.34

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2025 – unaudited

	Note	**30 June 2025** *RMB'000*	31 December 2024 *RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**4,717,875**	4,791,782
Right-of-use assets		**492,427**	479,821
Goodwill		**3,599,182**	3,599,182
Other intangible assets		**7,132**	7,781
Investments in associates		**1,041,053**	993,602
Receivables from invest-operate-transfer ("**IOT**") hospitals		**7,679**	8,231
Financial assets measured at fair value through profit or loss ("**FVTPL**")		**40,185**	34,855
Deferred tax assets		**11,965**	33,223
Other non-current assets		**153,639**	130,535
Total non-current assets		**10,071,137**	10,079,012
CURRENT ASSETS			
Inventories		**300,626**	301,662
Trade and bills receivables	*11*	**1,373,103**	1,412,156
Contract assets		**6,255**	4,605
Prepayments, deposits and other receivables		**460,570**	427,199
Due from related parties		**54,157**	39,730
Restricted and pledged bank deposits		**75,134**	76,453
Financial assets measured at FVTPL		**50,000**	–
Cash and cash equivalents		**1,194,647**	977,333
Total current assets		**3,514,492**	3,239,138
CURRENT LIABILITIES			
Trade and bills payables	*12*	**1,679,586**	1,696,260
Other payables and accruals		**1,593,360**	1,588,996
Due to related parties		**462,564**	435,403
Interest-bearing bank borrowings		**850,146**	701,717
Lease liabilities		**59,655**	51,946
Deferred income		**–**	3,769
Tax payable		**79,328**	21,295
Total current liabilities		**4,724,639**	4,499,386

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONT'D)

At 30 June 2025 – unaudited

	Note	30 June 2025 RMB'000	31 December 2024 RMB'000
NET CURRENT LIABILITIES		**(1,210,147)**	(1,260,248)
TOTAL ASSETS LESS CURRENT LIABILITIES		**8,860,990**	8,818,764
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowings		**–**	734,700
Lease liabilities		**114,850**	107,239
Defined benefit plan obligations		**397,017**	393,843
Deferred income		**36,406**	38,827
Deferred tax liabilities		**24,592**	25,211
Due to a related party		**500,000**	–
Other liabilities		**19,481**	20,876
Total non-current liabilities		**1,092,346**	1,320,696
NET ASSETS		**7,768,644**	7,498,068
EQUITY			
Equity attributable to owners of the Company			
Share capital		**267**	267
Reserves		**6,449,118**	6,213,269
		6,449,385	6,213,536
Non-controlling interests		**1,319,259**	1,284,532
TOTAL EQUITY		**7,768,644**	7,498,068

NOTES

1. CORPORATE INFORMATION

China Resources Medical Holdings Company Limited is a limited liability company incorporated in the Cayman Islands.

During the period, the Company and its subsidiaries (collectively referred to as the "**Group**") were mainly engaged in (i) provision of general healthcare services; (ii) provision of hospital management services, sale of pharmaceuticals, medical devices and medical consumables and provision of other services in Chinese Mainland.

2.1 BASIS OF PREPARATION

The interim financial report of the Group for the six months ended 30 June 2025 has been prepared in accordance with International Accounting Standard ("**IAS**") 34 *Interim Financial Reporting*, issued by the International Accounting Standards Board ("**IASB**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements as detailed in note 2.2. The interim financial report does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024. The auditor of the Company, KPMG, has expressed an unqualified opinion on these financial statements in their report dated 25 March 2025.

The interim financial report has been prepared under the historical cost convention, except for financial assets measured at FVTPL which have been measured at fair value. The financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand, except when otherwise indicated.

As at 30 June 2025, the Group's current liabilities exceeded its current assets by RMB1.21 billion. As at 30 June 2025, the Group has unutilised bank facilities of approximately HKD3.40 billion and RMB4.92 billion (equivalent to approximately RMB8.02 billion in total). The directors of the Company have reviewed the Group's cash flow forecast for the next twelve months and are of the opinion that the Group will have sufficient facilities to repay the liabilities. Accordingly, the directors of the Company consider it is appropriate to prepare the interim financial report on a going concern basis.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has applied the amendments to IAS 21, the effects of changes in foreign exchange rates — Lack of exchangeability, issued by the IASB to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim financial report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new or revised standard that is not yet effective for the current accounting period.

3. OPERATING SEGMENT INFORMATION

Management monitors the results of the Group's operating segments separately for the purpose of facilitating decision-making process of resource allocation and performance assessment. During the reporting period, the reportable segments of the Group are as follows:

(a) Hospital business: includes out-patient and emergency business, in-patient business corresponding to self-owned hospitals.

(b) Other business: includes operation management services, supply chain services and other services provided to participating hospitals and IOT/OT hospitals.

Segment performance is evaluated based on reportable segment results, which are measurements of adjusted profit/loss before tax. The adjusted profit/loss before tax is measured consistently with the Group's profit/loss before tax except that change in fair value of an equity investment measured at FVTPL, investment income on financial assets measured at FVTPL, other unallocated income and gains, foreign exchange differences, net, other unallocated losses and expenses are excluded from such measurement.

Segment assets exclude goodwill, unallocated investments in associates, financial assets measured at FVTPL, cash and cash equivalents and pledged deposits and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude interest-bearing bank borrowings and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Inter-segment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The following is an analysis of the Group's revenue and results, and assets and liabilities by reportable operating segments.

Segment revenue and results

	Hospital Business *RMB'000*	Other Business *RMB'000*	Total *RMB'000*
Six months ended 30 June 2025			
Segment revenue	**4,258,616**	**266,187**	**4,524,803**
Inter-segment revenue	**–**	**–**	**–**
Consolidated revenue	**4,258,616**	**266,187**	**4,524,803**
Segment cost	**(3,588,771)**	**(223,505)**	**(3,812,276)**
Other income	**44,066**	**206,947**	**251,013**
Other gains and losses, net	**(5,660)**	**–**	**(5,660)**
Share of profits of associates	**–**	**47,450**	**47,450**
Administrative and other operating expenses	**(431,037)**	**(5,913)**	**(436,950)**
Finance costs	**(8,243)**	**–**	**(8,243)**
Impairment losses on financial and contract assets, net	**(14,263)**	**1,174**	**(13,089)**
Segment results	**254,708**	**292,340**	**547,048**
Other unallocated income and gains			**7,168**
Change in fair value of financial assets measured at FVTPL			**5,330**
Foreign exchange differences, net			**(724)**
Other unallocated losses and expenses			**(50,699)**
Profit before tax			**508,123**

	Hospital Business *RMB'000*	Other Business *RMB'000*	Total *RMB'000*
Six months ended 30 June 2024			
Segment revenue	4,600,005	376,329	4,976,334
Inter-segment revenue	–	–	–
Consolidated revenue	4,600,005	376,329	4,976,334
Segment cost	(3,677,361)	(262,625)	(3,939,986)
Other income	55,672	2,388	58,060
Other gains and losses, net	(4,275)	–	(4,275)
Share of profits of associates	–	44,329	44,329
Selling and distribution expenses	(758)	(1,680)	(2,438)
Administrative and other operating expenses	(440,481)	(14,352)	(454,833)
Finance costs	(9,632)	–	(9,632)
Impairment losses on financial and contract assets, net	(2,334)	4,097	1,763
Segment results	520,836	148,486	669,322
Other unallocated income and gains			10,947
Change in fair value of financial assets measured at FVTPL			(5,515)
Foreign exchange differences, net			(117)
Other unallocated losses and expenses			(47,309)
Profit before tax			627,328

Segment assets and liabilities

	Hospital business *RMB'000*	**Other business** *RMB'000*	**Total** *RMB'000*
As at 30 June 2025			
Segment assets	**8,780,580**	**1,366,473**	**10,147,053**
Unallocated assets			**7,573,124**
Elimination of inter-segment receivables			**(4,134,548)**
Total assets			**13,585,629**
Segment liabilities	**4,799,278**	**21,617**	**4,820,895**
Unallocated liabilities			**5,130,638**
Elimination of inter-segment payables			**(4,134,548)**
Total liabilities			**5,816,985**

	Hospital business *RMB'000*	Other business *RMB'000*	Total *RMB'000*
As at 31 December 2024			
Segment assets	8,889,773	1,348,719	10,238,492
Unallocated assets			7,031,490
Elimination of inter-segment receivables			(3,951,832)
Total assets			13,318,150
Segment liabilities	4,865,659	20,870	4,886,529
Unallocated liabilities			4,885,385
Elimination of inter-segment payables			(3,951,832)
Total liabilities			5,820,082

4. REVENUE

Disaggregated revenue information

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Types of goods or services		
In-patient	**2,446,041**	2,704,719
Out-patient and emergency	**1,812,575**	1,895,286
General healthcare services	**4,258,616**	4,600,005
Other services	**266,187**	376,329
Total	**4,524,803**	4,976,334
Timing of revenue recognition		
A point in time	**2,051,482**	2,222,600
Over time	**2,473,321**	2,753,734
Total	**4,524,803**	4,976,334

All of the Group's revenue is derived from the PRC.

5. OTHER INCOME

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Interest and investment income on:		
Financial assets at FVTPL	**238**	601
Receivables from IOT hospitals	**524**	2,376
Bank deposits	**4,443**	8,223
Dividend income on financial assets measured at FVTPL	**2,880**	3,589
Government grants	**8,477**	5,816
Write-off of payables	**4,234**	14,468
Enforcement payment from "Yan Hua Hospital"	**206,423**	–
Others	**30,962**	33,934
	258,181	69,007

6. OTHER GAINS AND LOSSES, NET

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Change in fair value of financial assets measured at FVTPL	**5,330**	(5,515)
Foreign exchange differences, net	**(724)**	(117)
Loss on disposal of items of property, plant and equipment	**(796)**	(812)
Others	**(4,872)**	(3,520)
	(1,062)	(9,964)

7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Cost of inventories sold	**1,910,247**	2,064,594
Depreciation of property, plant and equipment	**259,467**	274,200
Depreciation of right-of-use assets	**28,693**	26,387
Amortisation of intangible assets (included in cost of sales)	**649**	2,135
Total depreciation and amortisation	**288,809**	302,722
Impairment of trade receivables, net	**12,689**	(344)

8. INCOME TAX

The PRC enterprise income tax has been provided at the rate of 25% (six months ended 30 June 2024: 25%) on the estimated assessable income arising in the PRC during the period. No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong during the period (six months ended 30 June 2024: Nil).

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Current — Mainland China	**113,236**	116,458
Deferred	**20,639**	(785)
Total tax charge for the period	**133,875**	115,673

9. DIVIDEND

	For the six months ended 30 June **2025** *RMB'000*	2024 *RMB'000*
Dividend recognised as distribution during the period:		
Final 2024 – RMB8.2 cents (2023: RMB6.0 cents)	**106,327**	77,860
Less: Dividend for shares held under the Share Award Scheme	**(2,655)**	(1,945)
	103,672	75,915

	For the six months ended 30 June **2025** *RMB'000*	2024 *RMB'000*
Interim dividend declared after the interim period of RMB5.0 cents per ordinary share (2024: RMB5.0 cents)	**64,834**	64,834

The interim dividend has not been recognised as a liability at the end of the reporting period.

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit attributable to ordinary equity holders of the parent of RMB339,521,000 (six months ended 30 June 2024: RMB433,949,000), and the weighted average number of ordinary shares of 1,264,292,000 (2024: 1,264,292,000) in issue during the interim period.

The Group had no potentially dilutive ordinary shares in issue during the interim period.

11. TRADE AND BILLS RECEIVABLES

	30 June 2025 *RMB'000*	31 December 2024 *RMB'000*
Trade receivables		
Public medical insurance program	**1,140,394**	1,279,842
Other customers	**470,337**	362,176
Bills receivable	**313**	182
	1,611,044	1,642,200
Impairment	**(237,941)**	(230,044)
	1,373,103	1,412,156

The Group's trading terms with its corporate customers are mainly on credit, except for new customers, where payment in advance is normally required. The credit periods range from 30 to 180 days. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade and bills receivable balances. Trade and bills receivables are non-interest-bearing.

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2025 *RMB'000*	31 December 2024 *RMB'000*
Within 1 year	**1,341,036**	1,383,399
1 to 2 years	**28,079**	24,450
Over 2 years	**3,988**	4,307
	1,373,103	1,412,156

12. TRADE AND BILLS PAYABLES

An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the date of delivery of goods, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
Within 60 days	**744,132**	1,000,117
61 to 180 days	**708,233**	565,302
Over 180 days	**227,221**	130,841
	1,679,586	1,696,260

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

In the first half of 2025, the Company actively responded to changes in the external environment by strengthening its foundation in comprehensive medical care, cultivating specialized disciplines, and exploring derivative businesses. For comprehensive medical care, the Company continued integrating into regional medical planning, making positive progress in key hospital disciplines development and scientific research innovation, enhancing management refinement of medical insurance, upgrading the functions of the "Runxin" one-stop service center to improve patient experience, and implemented AI to empower more medical service scenarios. For specialized disciplines, initial progress was made in neurology, health management, rehabilitation, and mental health fields. The Company continuously strengthened technological empowerment in neurology, promoted specialized development in health management, built a three-tier rehabilitation network, advanced integrated clinical rehabilitation, fostered multi-party collaboration and co-governance in mental health, and expanded the service network. For derivative businesses, the Company continued to explore new models combining medical care, industry, academia, and research, achieving improvements in both the quantity and quality of newly signed GCP projects.

Scale of our operation

As of June 30, 2025, the Group managed and operated a total of 103 medical institutions in 10 provinces and cities in the PRC. During the Reporting Period, the number of out-patient and emergency visits and in-patient visits of our self-owned hospitals were approximately 5,100,000 and 270,000, respectively, representing the respective period-over-period increase of 1.0% and decrease of 3.9%.

List of Medical Institutions under the Group's Management and Operation

Province/City	Grade III Hospitals	Grade II Hospitals	Grade I Hospitals and Community Centres	Clinics & Other Medical Institutions	Total
Beijing	3	2	7	8	20
Liaoning	5	11	9	4	29
Jiangxi	1	3	4	2	10
Shandong	–	1	1	3	5
Shanxi	–	1	–	–	1
Jiangsu	–	1	–	–	1
Anhui	1	1	16	2	20
Hubei	2	–	3	6	11
Guangdong	1	1	–	2	4
Guangxi	–	1	1	–	2
Total	13	22	41	27	103

Note:

(1) The hospital grading system in Chinese Mainland is a review system implemented by the health administrative departments of the People's Republic of China for medical institutions within their administrative jurisdiction, including the criteria for reviewing hospital qualifications. Currently, China operates a three-tier medical service system; Grade III hospitals, as high-quality medical resources, represent the highest level of medical qualifications in Chinese Mainland.

Operating data for 2025H1

			Number of patients		Revenue from medical business *(RMB'000)*			
Type	Number of beds in operation	Utilization rate of beds	Out-patient and emergency	In-patient	Revenue from out-patient and emergency visits	Revenue from in-patient visits	Revenue from physical examination	Total
Self-owned Hospitals	**18,286**	**80.57%**	**5,103,793**	**270,957**	**1,721,993**	**2,446,041**	**90,582**	**4,258,616**

Operating data for 2024H1

			Number of patients		Revenue from medical business *(RMB'000)*			
Type	Number of beds in operation	Utilization rate of beds	Out-patient and emergency	In-patient	Revenue from out-patient and emergency visits	Revenue from in-patient visits	Revenue from physical examination	Total
Self-owned Hospitals	18,646	79.93%	5,053,642	282,090	1,810,738	2,704,719	84,548	4,600,005

Note:

1. In respect of the operating data statistics, the abovementioned self-owned hospitals refer to all consolidated hospitals.

Financial data

The table below sets out the key financial figures of the Group by business segments for the specific periods:

	2025H1	2024H1	Period-over-Period Change	
	RMB'000	*RMB'000*	*RMB'000*	*Percentage*
Hospital Business [(1)]				
Revenue	**4,258,616**	4,600,005	–341,389	–7.4%
— Revenue from out-patient and emergency visits	**1,812,575**	1,895,286	–82,711	–4.4%
— Revenue from in-patient visits	**2,446,041**	2,704,719	–258,678	–9.6%
Segment gross profit	**669,845**	922,644	–252,799	–27.4%
Segment results	**254,708**	520,836	–266,128	–51.1%
Other Business [(2)]				
Revenue	**266,187**	376,329	–110,142	–29.3%
Segment gross profit	**42,682**	113,704	–71,022	–62.5%
Segment results	**292,340**	148,486	143,854	96.9%
Total				
Revenue	**4,524,803**	4,976,334	–451,531	–9.1%
Segment gross profit	**712,527**	1,036,348	–323,821	–31.2%
Segment results	**547,048**	669,322	–122,274	–18.3%

Notes:

During the Reporting Period:

(1) Hospital business includes: out-patient and emergency business and in-patient business corresponding to self-owned hospitals.

(2) Other business include: operation management services, supply chain services and other services provided to participating hospitals and IOT (the "**invest-operate-transfer**" model)/OT (the "**operate-transfer**" model) hospitals. As at June 30, 2025, IOT hospitals include Mentougou Traditional Chinese Medicine Hospital and Mentougou Healthcare Hospital for Women and Children.

Hospital Business

During the Reporting Period, the revenue of the hospital business segment was RMB4,259 million, representing a period-over-period decrease of 7.4%. Among which, out-patient and emergency visits increased by 1.0% and in-patient visits decreased by 3.9%. Affected by a decrease in average medical insurance fee per visit, each of the revenue per out-patient and emergency visit and the revenue per in-patient visit decreased by 5.8%.

During the Reporting Period, we made efforts to reduce the impact of the decline in revenue per visit on the hospital business's profit through improving quality and efficiency. The gross profit of the hospital business segment was RMB670 million, representing a period-over-period decrease of 27.4%, with a gross profit margin of 15.7% (Corresponding Period: 20.1%); the profit of the hospital business segment recorded RMB255 million, representing a period-over-period decrease of 51.1%.

Other Business

During the Reporting Period, the revenue of other business was RMB266 million, representing a period-over-period decrease of 29.3%, and the segment profit of other business was RMB292 million, representing a period-over-period increase of 96.9%. After excluding the one-off compensation for the management fees and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group, the segment profit would be RMB86 million, representing a period-over-period decrease of 42.1%. During the Reporting Period, the IOT business of the Company has been scaled back, the corresponding profit contribution of which has decreased during the Reporting Period.

Administrative and other operating expenses

During the Reporting Period, the Group's administrative and other operating expenses totaled RMB470 million, decreased by 0.3% period-over-period, due to the effectiveness of expense control measures.

Finance costs

During the Reporting Period, the finance cost of the Group amounted to approximately RMB27.32 million (Corresponding Period: approximately RMB39.84 million). The decrease in the finance costs was in line with the Group's proactive adjustment of debt structure, resulting in the reduction in both the scale of interest-bearing liabilities and the weighted average financing cost.

Income tax

During the Reporting Period, the Group's income tax amounted to approximately RMB134 million (Corresponding Period: approximately RMB116 million), increased by 15.7% period-over-period. The increase in income tax is mainly due to the one-off compensation for the management fees and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group, which resulted in an increase in domestic taxable income.

Net profit

As a result of the foregoing, the Group recorded a net profit of RMB374 million for the Reporting Period, representing a period-over-period decrease of 26.9%. After excluding the one-off compensation for the management fees and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group and the corresponding enterprise income tax, the net profit would decrease by 57.1% as compared to the corresponding period in 2024. Such decrease in net profit was mainly attributable to the decrease in operating profits of member medical institutions which is in turn caused by a decrease in average medical insurance fee per visit. Meanwhile, the IOT business of the Company has been scaled back, the corresponding profit contribution of which was decreased.

Liquidity and Financing

We adopt a prudent treasury management policy to maintain a solid and healthy financial position. The Group funds its operations principally from cash generated from its operations and bank facilities. Its cash needs relate primarily to operating activities, business expansion, repayment of liabilities as they become due, capital expenditures, and interest and dividend payments.

As at June 30, 2025, the Group's consolidated bank balances and cash, certificate of deposits and bank financial products amounted to approximately RMB1.320 billion in total (December 31, 2024: approximately RMB1.054 billion) which were primarily denominated in RMB.

As at June 30, 2025, the Group had obtained offshore revolving term loan facility of HK$3.40 billion (or its equivalent in U.S. dollar or RMB), among them, HK$2.60 billion is of a term of one year which shall be automatically renewed if the relevant bank does not notify otherwise. In addition, the Group had also obtained from banks onshore facilities of RMB4.11 billion. As at June 30, 2025, the Group had bank borrowings of RMB850 million, which consists entirely of interest-bearing bank loans (as at December 31, 2024, the Group had bank borrowings of RMB1.436 billion, among them, RMB1.435 billion was interest-bearing bank loans and RMB1.391 million was financially discounted bank loans), all the bank borrowings consists entirely of fixed interest rates, and unutilized bank facilities of amounted to approximately HK$3.40 billion and RMB4.92 billion (equivalent to approximately RMB8.02 billion in total). As at June 30, 2025, the Group also had borrowing from related parties, for a term of three years, of RMB500 million.

Gearing Ratio

As at June 30, 2025, on the basis of interest-bearing borrowings divided by total assets, the Group's gearing ratio was 9.9% (December 31, 2024: 10.8%). In addition, the carrying value of each of our wealth management products as at June 30, 2025 did not exceed 5% of the Group's total asset value.

Exposure to Fluctuation in Exchange Rates, the Interest Rate Risk and Other Risks

The Group does not undertake operating transactions in foreign currencies. As of June 30, 2025, all of the Group's bank borrowings are denominated in RMB.

The Group has not used any derivative contracts to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and considers hedging against significant foreign exchange risk exposure should such need arise.

We are also exposed to risk of talent shortage, and therefore we have been taking an active approach to attract, train and retain sufficient qualified doctors, management personnel and other medical staff members, in the absence of which the business of hospitals affiliated to the Group would be affected to a certain extent. Please refer to the paragraph headed "Management Discussion and Analysis — Employees and Remuneration Policy" for the relevant measures undertaken.

We also recognise that our relationship with patients and partners is key to the resilient development of the Group. We strive to provide quality services and medical staffs with extensive experiences to our patients. By leveraging on sophisticated medical skills and equipment, we try our best to cater to our patients' needs for medical treatments. We also cooperate with our partners to achieve the sustainable development of our business.

Contingent Liabilities

As at June 30, 2025, the Group did not have any contingent liabilities or guarantees that would have a material impact on the financial position or operations of the Group.

Pledge of Assets

As of June 30, 2025, the Group did not have any material pledge of assets.

Employees and Remuneration Policy

As of June 30, 2025, the Group had a total of 19,735 full-time employees (December 31, 2024: 19,953 employees). For the Reporting Period, the staff costs (including Directors' remuneration in the form of salaries and other benefits) was approximately RMB1,716 million (Corresponding Period: RMB1,704 million).

The Group ensured that the remuneration packages of employees remain competitive and the remuneration level of its employees was determined on the basis of performance with reference to the profitability of the Group, industry remuneration standards and market conditions within the general framework of the Group's remuneration system.

The Group had adopted the Share Award Scheme so as to provide incentives or rewards to Eligible Persons for their contribution or potential contribution to the Company and/or any of its subsidiaries. The Share Award Scheme was expired on July 6, 2024. There has been no change to the number and status of award shares under the Share Award Scheme since the expiration date of the Share Award Scheme. For details of the Share Award Scheme, please refer to the section headed "Share Award Scheme" in the Company's annual report for the year ended December 31, 2024.

For talent acquisition and continuous development, the Group offers training programs as well as leadership and talent development programs for talents with different academic backgrounds. The Group believes that direct and effective communication is essential for good partnership built-up between management and employees. The Group holds regular meetings and forums to brief employees on the Company's developments and obtain their feedbacks and suggestions.

Contractual Obligations

As at June 30, 2025, the Group did not have any significant contractual obligations arisen outside of the ordinary and usual course of business of the Group and of a capital nature that would have a material effect on the financial position or operations of the Group.

Interim Dividend

The Board has resolved to declare an interim dividend of RMB5 cents per Share (equivalent to HK$5.48 cents per Share at the exchange rate of RMB1:HK$1.09590, being the average benchmark exchange rate of RMB to HK$ as published by the People's Bank of China during the five business days ending on Tuesday, August 26, 2025 (inclusive)) for the six months ended June 30, 2025 (the "**2025 Interim Dividend**") (Corresponding Period: RMB5 cents per Share). The 2025 Interim Dividend will be distributed on Friday, October 24, 2025 to Shareholders whose names appear on the register of members of the Company on Monday, September 15, 2025, being the record date for determining Shareholders' entitlement to the 2025 Interim Dividend.

The 2025 Interim Dividend will be payable in cash to each Shareholder in HK$, unless an election is made to receive the same in RMB. Shareholders will be given the option to elect to receive all (but not part, save in the case of HKSCC Nominees Limited, which may elect to receive part of its entitlement in RMB) of the 2025 Interim Dividend in RMB. To make such election, Shareholders should complete the dividend currency election form, which is expected to be despatched to Shareholders on or around Monday, September 22, 2025, and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Thursday, October 9, 2025. Shareholders who are minded to elect to receive all of the 2025 Interim Dividend in RMB by cheques should note that (i) they should ensure that they have an appropriate bank account to which the RMB cheques for dividend can be presented for payment; and (ii) there is no assurance that RMB cheques can be cleared without material handling charges or delay in Hong Kong or that RMB cheques will be honoured for payment upon presentation outside Hong Kong. The cheques are expected to be posted to the relevant Shareholders by ordinary post on Friday, October 24, 2025 at the Shareholders' own risk.

For the avoidance of doubt, if no election is made by a Shareholder or no duly completed dividend currency election form in respect of that Shareholder is received by the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, by 4:30 p.m. on Thursday, October 9, 2025, such Shareholder will automatically receive the 2025 Interim Dividend in HK$.

All payments of the 2025 Interim Dividend in HK$ will be made in the usual way on Friday, October 24, 2025. If Shareholders wish to receive the 2025 Interim Dividend in HK$ in the usual way, no action is required. Shareholders should seek professional advice from their own tax advisors regarding the possible tax implications of such dividend payment.

Closure of Register of Members

For determining the entitlement to the 2025 Interim Dividend, the register of members of the Company will be closed from Friday, September 12, 2025 to Monday, September 15, 2025, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for the entitlement to the 2025 Interim Dividend, all transfers of shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. (Hong Kong time) on Thursday, September 11, 2025.

Events After the Reporting Period

The Company has submitted a case filing application in relation to the Yan Hua IOT Agreement dispute to the Beijing Second Intermediate People's Court in June 2025, seeking the Court's ruling for termination of the Yan Hua IOT Agreement, and ordering Yan Hua Phoenix and/or Yan Hua Hospital to pay the relevant compensation for breach of contract and to return the relevant funds under the Yan Hua IOT Agreement (the "**New Litigation**"). In July 2025, the Company has received service documents issued by the Beijing Second Intermediate People's Court, confirming that the court has formally accepted the filing of the New Litigation on June 24, 2025. For more details, please refer to the section "OTHER INFORMATION — Yan Hua IOT Agreement Dispute" as set out below and the announcement of the Company dated July 7, 2025.

Save as disclosed above, the Group had no other significant subsequent events since the end of the Reporting Period and up to the date of this announcement.

Significant Investments, Acquisitions and Disposals, and Investments in Joint Venture(s) and Associate(s)

As at June 30, 2025, the Group did not have any significant investments. Save as disclosed in the section headed "Investments in Associates — JR Renkang & JR Holdings" below, the Group did not have any significant acquisitions and disposals of subsidiaries, associates or joint ventures during the Reporting Period.

Investments in Associates — JR Renkang & JR Holdings

On June 28, 2020, the Group entered into a restructuring agreement on the establishment of two associates with Jing Mei Group, pursuant to which Beijing Jing Run Renkang Hospital Management Co., Ltd. ("**JR Renkang**") and Beijing Jing Run Renkang Holdings Co., Ltd. ("**JR Holdings**") were established and held by the Group and Jing Mei Group as to 49% and 51%, respectively. Upon establishment, JR Renkang and JR Holdings became associates of the Group. Pursuant to the abovementioned agreement, JR Holdings has become the sponsor of the Jing Mei Hospital Group and JR Renkang has been providing hospital management services to the Jing Mei Hospital Group. Please refer to the announcement of the Company dated June 28, 2020 for further details.

Future Plans for Material Investment or Capital Assets

As at the date of this announcement, there are currently no concrete plans to acquire any material investment or capital assets other than those conducted in the Group's ordinary course of business.

FUTURE OUTLOOK

Moving forward, the Company will continue to be patient-centered, align with new health demand trends, and provide the target groups with more professional, effective, economical, and caring full-cycle health services. For comprehensive medical care, the Company will keep building its own and the regions' discipline brands, develop a full-cycle health service model, and explore expansion into non-insurance-covered services. For specialized disciplines, it will accelerate the construction of the neurology specialties alliance, enhance the influence of neurology specialties, and expand major client channels and service formats in health management. For derivative businesses, the Company will continuously improve supply chain efficiency, further increase the quantity and quality of GCP projects, and accelerate exploration of "medical + Internet" business.

COMPLIANCE WITH THE CG CODE

The Company recognises the importance of incorporating elements of good corporate governance into the management structures and internal control procedures of the Group so as to achieve effective accountability and safeguard the interests of the Shareholders.

The Company confirms that it has complied with all applicable code provisions of the CG Code contained in Part 2 of Appendix C1 to the Listing Rules during the Reporting Period, save and except the following:

Pursuant to Code Provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. With effect from June 19, 2025, Mr. YU Hai, the then chief executive officer of the Company, was also appointed as the chairman of the Board. Although Mr. YU Hai concurrently serving as the chairman of the Board and the chief executive officer of the Company resulted in the Company's deviation from Code Provision C.2.1, the Board believes that with the support of the management, vesting the duties and responsibilities of both chairman of the Board and the chief executive officer of the Company by the same person can facilitate execution of the Group's business strategies and boost effectiveness of its operation. In addition, under the supervision by the Board which currently consists of two executive Directors, one non-executive Director and four independent non-executive Directors, the interest of the Shareholders will continue to be adequately and fairly represented.

Code Provision F.2.2 (re-numbered as Code Provision F.1.3 with effect from July 1, 2025) of Part 2 of the CG Code stipulates that the chairman of the board should attend annual general meeting. The then chairman of the Board was unable to attend the annual general meeting of the Company held on June 5, 2025 ("**2025 AGM**") due to other work arrangements. Mr. YU Hai, the chief executive officer of the Company, attended and acted as the chairman of the 2025 AGM. The then chairman of the Audit Committee, chairman of the remuneration committee of the Company and members of the nomination committee of the Company were available to answer questions at the 2025 AGM.

The Board will review its corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code (on terms no less exacting than the required standard set out in the Model Code) as its own code of conduct for dealings in securities of the Company by the Directors. Having made specific enquiry with all Directors, the Company confirmed that all Directors complied with the Model Code throughout the Reporting Period. Senior management, executives and staff who, because of their offices in the Company, are likely to possess inside information of the Company have also been requested to comply with the provisions of the Model Code and the Company confirmed that there was no incident of non-compliance of the Model Code by such employees throughout the Reporting Period.

OTHER INFORMATION

Yan Hua IOT Agreement Dispute

In respect of the litigation case between the Company and the Yanhua Parties (i.e. the Yan Hua Phoenix and Yan Hua Hospital) regarding the performance of the Yan Hua IOT Agreement in 2019, the Beijing Higher People's Court handed down the final judgment (2020 Jing Minzhong No.110) on November 22, 2021, which rejected the appeal filed by the Yanhua Parties in 2020 and upheld the original judgment in 2019 as follows: the major details are as follows: (1) the unilateral termination of Yan Hua IOT Agreement by Yan Hua Phoenix and Yan Hua Hospital is declared to be void and that the parties shall continue to perform its obligations under the Yan Hua IOT Agreement; (2) the amount of RMB14,400,000, being the damages for breach of the Yan Hua IOT Agreement, is to be paid by Yan Hua Phoenix to CR Hospital Management & Consulting; (3) other reliefs sought by CR Hospital Management & Consulting shall be dismissed; and (4) other counterclaims of Yan Hua Phoenix and Yan Hua Hospital shall be dismissed. As the Yanhua Parties have been negligent in complying with the abovementioned final judgment, the Company then filed an application for enforcement with the Beijing Second Intermediate People's Court in January 2022, and then accordingly received the liquidated damages amounted to RMB14,400,000 and related overdue fine paid by Yan Hua Phoenix through the court enforcement procedure in April 2022. However, due to the Yanhua Parties' persistent refusal to perform the Yan Hua IOT Agreement, the Company brought a separate lawsuit against the Yanhua Parties in September 2022 to seek compensation for the losses suffered by the Company as a result of the Yanhua Parties' breach of the Yanhua IOT Agreement (including the management fee and supply chain fee receivable by the Company from 2019 to the filing date).

The Beijing Second Intermediate People's Court handed down the original judgment on December 22, 2023, adjudicating as follows: (1) ordering that Yan Hua Hospital should pay RMB3,057,500 for the annual repayment of investment and, in addition, related overdue fine; (2) ordering that the Yanhua Parties should pay RMB41,237,300 for the loss of hospital management fee and, in addition, related overdue fine; and (3) ordering that the Yanhua Parties should pay RMB146,666,700 for the loss from the cessation of comprehensive service transaction and, in addition, loss of interest. Both parties appealed against the original judgment. Subsequently, on December 27, 2024, the Beijing High People's Court has ruled to agree with the withdrawal of the appeal by the Yanhua Parties, and handed down the final judgment upholding the original judgment. On February 20, 2025, the Company received the enforcement payment of RMB209,480,000 transferred by the Court.

The Company has submitted a case filing application in relation to the Yan Hua IOT Agreement dispute to the Beijing Second Intermediate People's Court in June 2025, seeking the Court's ruling for termination of the Yan Hua IOT Agreement, and ordering Yan Hua Phoenix and/or Yan Hua Hospital to pay the relevant compensation for breach of contract and to return the relevant funds under the Yan Hua IOT Agreement (the "**New Litigation**"). The Company has received service documents issued by the Beijing Second Intermediate People's Court, confirming that the court has formally accepted the filing of the New Litigation on June 24, 2025.

Please refer to the announcements published by the Company on January 15, 2019, January 21, 2019, April 17, 2019, November 23, 2021, February 21, 2025 and July 7, 2025 for more details.

The Company will issue further announcements in a timely manner in accordance with the requirements of the Listing Rules and the SFO, as and when required.

REVIEW OF INTERIM RESULTS

The Audit Committee has reviewed the unaudited consolidated interim results of the Group for the Reporting Period and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.

The interim financial report for the six months ended June 30, 2025 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of interim financial information performed by the independent auditor of the entity", issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the interim report to be published.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale or transfer of treasury shares as defined under the Listing Rules). The Company did not have any treasury shares (as defined under the Listing Rules) as at June 30, 2025.

PUBLICATION OF THE UNAUDITED INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange at www.hkexnews.hk and of the Company at www.crmedical.hk, respectively. The interim report of the Company for the Reporting Period will be published on the Stock Exchange's and the Company's websites, respectively, in due course.

DEFINITIONS

"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors of our Company
"CG Code"	Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"Chairman"	the chairman of our Board
"China" or "PRC"	the People's Republic of China excluding, for the purpose of this announcement, Taiwan, the Macau Special Administrative Region and Hong Kong
"Company" or "our Company" or "China Resources Medical"	China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability on February 28, 2013
"Corresponding Period" or "2024 H1"	the period from January 1, 2024 to June 30, 2024
"CR Hospital Management & Consulting"	China Resources Hospital Management & Consulting Co. Ltd. (華潤醫院管理諮詢有限公司) (formerly known as Beijing Phoenix United Hospital Management Consulting Co. Ltd. (北京鳳凰聯合醫院管理諮詢有限公司), Beijing Phoenix United Hospital Management Co., Ltd. (北京鳳凰聯合醫院管理有限公司) and Beijing Phoenix United Hospital Management Joint Stock Co., Ltd. (北京鳳凰聯合醫院管理股份有限公司)), a limited liability company established under the laws of the PRC on November 6, 2007, and a wholly-owned subsidiary of our Company
"Director(s)"	the director(s) of the Company

"Eligible Persons"	any of the (i) key management personnel including the Directors and senior management of the Group; (ii) employed experts as nominated by the Board; and (iii) core employees of the Group
"Group", "we" or "us"	our Company and its subsidiaries
"HK$" or "HKD" and "HK cent(s)" or "cent(s)"	Hong Kong dollar and cent(s), respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"IOT"	the "invest-operate-transfer" model
"IOT Hospitals"	third-party hospitals and clinics, which we manage and operate under the IOT model
"Jing Mei Group"	Beijing Jing Mei Group Company Limited* (北京京煤集團有限責任公司), a company established in the PRC with limited liability. Jing Mei Group is a wholly-owned subsidiary of Beijing Energy Holding Company Limited* (北京能源集團有限責任公司), which currently holds the entire interest in and the sponsorship of Jing Mei Hospital and its affiliated medical institutes
"Jing Mei Hospital"	Jing Mei Hospital* (北京京煤集團總醫院)
"Jing Mei Hospital Group"	collectively, Jing Mei Hospital and its affiliated grade I hospitals and community clinics
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"OT"	the "operate-transfer" model
"OT Hospital(s)"	third-party hospital(s) which the Group manages and operates under the OT model

"Reporting Period" or "2025H1"	the period from January 1, 2025 to June 30, 2025
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	share(s) with par value of HK$0.00025 each in the capital of our Company
"Shareholder(s)"	holder(s) of the Share(s)
"Share Award Scheme"	the share award scheme of the Company adopted by the Board pursuant to a resolution passed by the Board on July 7, 2014, as amended by the Board on May 25, 2015 and August 31, 2018
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"U.S. dollar" or "US$"	United States dollar, the lawful currency of the United States of America
"Yan Hua Hospital"	Yan Hua Hospital* (北京燕化醫院)
"Yan Hua Hospital Group"	collectively, Yan Hua Hospital and the community clinics affiliated with Yan Hua Hospital
"Yan Hua Hospital Investment Management Agreement"	the hospital investment management agreement dated February 4, 2008, which was supplemented in April 2008, December 2010, June 2011, July 2013, September 2013 and October 2013, and were entered into between CR Hospital Management & Consulting, Yan Hua Hospital and Yan Hua Phoenix
"Yan Hua IOT Agreement"	the hospital management right and investment framework agreement dated February 1, 2008 and the Yan Hua Hospital Investment Management Agreement, both of which were supplemented in April 2008, December 2010, June 2011, June 2013, July 2013, September 2013 and October 2013, entered into by CR Hospital Management & Consulting with Yan Hua Phoenix and Yan Hua Hospital Group

"Yanhua Parties"	Yan Hua Phoenix and Yan Hua Hospital
"Yan Hua Phoenix"	Beijing Yan Hua Phoenix Healthcare Asset Management Co., Ltd.* (北京燕化鳳凰醫療資產管理有限公司), a limited liability company incorporated under the laws of the PRC on July 18, 2005

* *Denotes English translation of the name of a Chinese entity and is provided for identification purposes only.*

By Order of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, August 26, 2025

As at the date of this announcement and following the resignation of Mr. SHAN Baojie with effect from the same date, the Board comprises Mr. YU Hai and Ms. YANG Min as executive Directors; Ms. GE Lu as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.